Editorial
doi: 10.1200/JCO.23.00270.
Epub 2023 Mar 23.
Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?
Affiliations
- PMID: 36952642
- DOI: 10.1200/JCO.23.00270
Item in Clipboard
Editorial
Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?
J Clin Oncol.
.
No abstract available
Comment on
-
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Similar articles
-
Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.Future Oncol. 2023 Dec;19(39):2585-2591. doi: 10.2217/fon-2023-0550. Epub 2023 Dec 11. Future Oncol. 2023. PMID: 38073492 Review.
-
PARP inhibition in castration-resistant prostate cancer.Future Oncol. 2016 Mar;12(5):577-80. doi: 10.2217/fon.16.1. Epub 2016 Jan 21. Future Oncol. 2016. PMID: 26792387 No abstract available.
-
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?Future Oncol. 2022 Dec;18(39):4235-4238. doi: 10.2217/fon-2022-0668. Epub 2023 Jan 18. Future Oncol. 2022. PMID: 36651304 No abstract available.
-
Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.Pharmacogenomics. 2021 Dec;22(18):1237-1250. doi: 10.2217/pgs-2021-0119. Epub 2021 Nov 3. Pharmacogenomics. 2021. PMID: 34729995 Review.
-
PARP inhibitors in castration-resistant prostate cancer.Cancer Treat Res Commun. 2020;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub 2020 Jul 22. Cancer Treat Res Commun. 2020. PMID: 32745972
Cited by
-
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760 Free PMC article.
-
Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?Transl Cancer Res. 2023 Oct 31;12(10):2448-2453. doi: 10.21037/tcr-23-1279. Epub 2023 Oct 3. Transl Cancer Res. 2023. PMID: 37969378 Free PMC article. No abstract available.
-
Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.Curr Oncol. 2023 Dec 4;30(12):10311-10324. doi: 10.3390/curroncol30120751. Curr Oncol. 2023. PMID: 38132385 Free PMC article.
-
Amelanotic primary cervical malignant melanoma: A case report and review of literature.World J Clin Oncol. 2024 Jul 24;15(7):953-960. doi: 10.5306/wjco.v15.i7.953. World J Clin Oncol. 2024. PMID: 39071457 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
